Is Karyopharm Therapeutics Inc. overvalued?

Karyopharm Therapeutics Inc. (KPTI) — key valuation metrics and fundamentals.

No verdict

Price

$1.62

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$36.7M

Dividend yield

0.0%

Return on equity

77.6%

Sector

Healthcare

Fair value compares KPTI's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks